Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NMPA Approval

Dapagliflozin Tablets

Approval Number

国药准字HJ20170205

CompanyASTRAZENECA AB

Registration Date

September 2, 2021

Previous Approval Numbers

H20170205

Drug Information

Generic Name

达格列净片

Trade Name

安达唐

Dosage Form

片剂

Strength

5mg(以C21H25ClO6计)

Drug Type

化学药品

Registration Date

September 2, 2021

Expiry Date

September 1, 2026

Company Information

Applicant Company

Company NameASTRAZENECA AB

Company Address

SE-151 85 Sӧdertälje, Sweden

Manufacturing Company

Company NameASTRAZENECA PHARMACEUTICALS LP

Company Address

4601 Highway 62 East, Mount Vernon, Indiana 47620, U.S.A.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy